Literature DB >> 17439981

Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes.

Juliane S Müller1, Agnes Herczegfalvi, Juan J Vilchez, Jaume Colomer, Linda L Bachinski, Violeta Mihaylova, Manuela Santos, Ulrike Schara, Marcus Deschauer, Michael Shevell, Chantal Poulin, Ana Dias, Ana Soudo, Marja Hietala, Tuula Aärimaa, Ralf Krahe, Veronika Karcagi, Angela Huebner, David Beeson, Angela Abicht, Hanns Lochmüller.   

Abstract

Dok ('downstream-of-kinase') family of cytoplasmic proteins play a role in signalling downstream of receptor and non-receptor phosphotyrosine kinases. Recently, a skeletal muscle receptor tyrosine kinase (MuSK)-interacting cytoplasmic protein termed Dok-7 has been identified. Subsequently, we and others identified mutations in DOK7 as a cause of congenital myasthenic syndromes (CMS), providing evidence for a crucial role of Dok-7 in maintaining synaptic structure. Here we present clinical and molecular genetic data of 14 patients from 12 independent kinships with 13 different mutations in the DOK7 gene. The clinical picture of CMS with DOK7 mutations is highly variable. The age of onset may vary between birth and the third decade. However, most of the patients display a characteristic 'limb-girdle' pattern of weakness with a waddling gait and ptosis, but without ophthalmoparesis. Respiratory problems were frequent. Patients did not benefit from long-term therapy with esterase inhibitors; some of the patients even worsened. DOK7 mutations have emerged as one of the major genetic defects in CMS. The clinical picture differs significantly from CMS caused by mutations in other genes, such as the acetylcholine receptor (AChR) subunit genes. None of the patients with DOK7 mutations had tubular aggregates in the muscle biopsy, implying that 'limb-girdle myasthenia (LGM) with tubular aggregates' previously described in literature may be a pathogenic entity distinct from CMS caused by DOK7 mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439981     DOI: 10.1093/brain/awm068

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  37 in total

1.  Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

Authors:  D Lashley; J Palace; S Jayawant; S Robb; D Beeson
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L.

Authors:  Peter T Hallock; Chong-Feng Xu; Tae-Ju Park; Thomas A Neubert; Tom Curran; Steven J Burden
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

3.  Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia.

Authors:  Teerin Liewluck; Duygu Selcen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-09-23       Impact factor: 3.217

4.  Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy.

Authors:  Stéphanie Bauché; Geoffroy Vellieux; Damien Sternberg; Marie-Joséphine Fontenille; Elodie De Bruyckere; Claire-Sophie Davoine; Guy Brochier; Julien Messéant; Lucie Wolf; Michel Fardeau; Emmanuelle Lacène; Norma Romero; Jeanine Koenig; Emmanuel Fournier; Daniel Hantaï; Nathalie Streichenberger; Veronique Manel; Arnaud Lacour; Aleksandra Nadaj-Pakleza; Sylvie Sukno; Françoise Bouhour; Pascal Laforêt; Bertrand Fontaine; Laure Strochlic; Bruno Eymard; Frédéric Chevessier; Tanya Stojkovic; Sophie Nicole
Journal:  J Neurol       Date:  2017-07-15       Impact factor: 4.849

5.  LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin.

Authors:  Ricardo A Maselli; Jose M Fernandez; Juan Arredondo; Carmen Navarro; Maian Ngo; David Beeson; Orla Cagney; D Colette Williams; Robert L Wollmann; Vladimir Yarov-Yarovoy; Michael J Ferns
Journal:  Hum Genet       Date:  2011-12-29       Impact factor: 4.132

6.  AAV9-DOK7 gene therapy reduces disease severity in Smn2B/- SMA model mice.

Authors:  Kevin A Kaifer; Eric Villalón; Caley E Smith; Madeline E Simon; Jose Marquez; Abigail E Hopkins; Toni I Morcos; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2020-07-30       Impact factor: 3.575

7.  Fatigue in Rapsyn-Deficient Zebrafish Reflects Defective Transmitter Release.

Authors:  Hua Wen; Jeffrey Michael Hubbard; Wei-Chun Wang; Paul Brehm
Journal:  J Neurosci       Date:  2016-10-19       Impact factor: 6.167

8.  Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7.

Authors:  A Ben Ammar; F Petit; N Alexandri; K Gaudon; S Bauché; A Rouche; D Gras; E Fournier; J Koenig; T Stojkovic; A Lacour; P Petiot; F Zagnoli; L Viollet; N Pellegrini; D Orlikowski; L Lazaro; X Ferrer; G Stoltenburg; M Paturneau-Jouas; F Hentati; M Fardeau; D Sternberg; D Hantaï; P Richard; B Eymard
Journal:  J Neurol       Date:  2009-12-11       Impact factor: 4.849

9.  Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.

Authors:  Ricardo A Maselli; Juan Arredondo; Orla Cagney; Jarae J Ng; Jennifer A Anderson; Colette Williams; Bae J Gerke; Betty Soliven; Robert L Wollmann
Journal:  Hum Mol Genet       Date:  2010-04-06       Impact factor: 6.150

10.  Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients.

Authors:  Duygu Selcen; Margherita Milone; Xin-Ming Shen; C Michel Harper; Anthony A Stans; Eric D Wieben; Andrew G Engel
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.